bayer.com
May 16, 2008
Nexavar Significantly Extends Overall Survival in Liver Cancer by 47 percent Trial Results Confirm Efficacy for Population Most Affected by the Disease Berlin, May 16, 2008 - Bayer HealthCare and Onyx Pharmaceuticals, Inc. today announced that Nexavar® (sorafenib) tablets significantly improved...
[read full story]